NCT07586202 A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC Status NOT_YET_RECRUITING Phase PHASE2
NCT07392658 Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations. Status RECRUITING Phase PHASE2
NCT07276399 A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer Status RECRUITING Phase PHASE3
NCT07227025 A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer Status RECRUITING Phase PHASE1/PHASE2
NCT06750094 A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy Status RECRUITING Phase PHASE3
NCT06667076 A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Status RECRUITING Phase PHASE2
NCT06662786 A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer Status RECRUITING Phase PHASE3
NCT06532032 A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT06507306 A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies Status RECRUITING Phase PHASE1
NCT06385080 A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer Status RECRUITING Phase PHASE1/PHASE2
NCT06116682 Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) Status RECRUITING Phase PHASE2
NCT06083857 PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT05908734 A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT05845450 Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) Status RECRUITING Phase PHASE2
NCT05801029 A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05663866 Premedication to Reduce Amivantamab Associated Infusion Related Reactions Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05653427 A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma Status TERMINATED Phase PHASE2
NCT05601973 Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05498428 A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer Status RECRUITING Phase PHASE2